Angus Dalgleish

This inventor holds 18 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 8 EPO patents. Top assignees: Ldn Pharma Limited, Onyvax Limited, Cancer Vaccine Institute. Active years: 2004-2026.

USPTO Granted Patents = 18 (Patent Applications = 9)

% Patents Active = 77.8

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 5)

Average Co-Inventor Count = 2.5

ph-index = 4

Forward Citations = 63(Granted Patents)

Location History:

Greater London, GB (2022)
London, GB (2004 - 2024)
London Greater London, GB (2024)

Company Filing History:

Cancer Vaccine Institute

patents

4. 1 out of 5

Akos Biosciences, Inc.

Jazz Pharmaceuticals Research UK Limited

patents

Years Active: 2004-2026

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12611405 - Agent that increases the expression of the BCL2-associated agonist of cell death for the treatment of cancer (2026-04-28),

2. 12161607 - Combination of cannabinoids in the treatment of leukemia (2024-12-10),

3. 12144807 - Priming of cancer cells with low dose naltrexone (2024-11-19),

4. 12029737 - Autoimmune therapy (2024-07-09),

5. 11885796 - Assay to identify anti-cancer agents (2024-01-30),

6. 11607423 - Combination of a cannabinoid and a chemotheraopeutic agent for the treatment of breast cancer (2023-03-21),

7. 11351165 - Agent that increases the expression of the opioid kappa 1 for the treatment of cancer (2022-06-07),

8. 11304943 - Combination for use in the treatment of lung cancer (2022-04-19),

9. 11065245 - Priming of cancer cells with low dose naltrexone (2021-07-20),

10. 11000486 - Combination of cannabinoids in the treatment of leukaemia (2021-05-11),

11. 10758514 - Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour (2020-09-01),

12. 9895438 - Treatment of cancer with naltrexone (2018-02-20),

13. 8545835 - Human prostate cell lines in cancer treatment (2013-10-01),

14. 8097244 - Human prostate cell lines in cancer treatment (2012-01-17),

15. 8034360 - Use of human prostate cell lines in cancer treatment (2011-10-11),

Title: The Innovative Mind of Angus Dalgleish

Introduction

Angus Dalgleish, based in Great Britain, is a notable figure in the pharmaceutical sector, particularly associated with LDN Pharma Limited. Although he currently holds no patents, his work and contributions to the field have been significant through his collaboration and innovation.

Latest Patents

As of now, Angus Dalgleish does not have any patents registered. However, his involvement in research and the development of pharmaceutical solutions could lead to innovative breakthroughs in the future.

Career Highlights

Angus has made substantial strides in his career, primarily working at LDN Pharma Limited. His role at the company involves guiding projects that aim to enhance therapeutic options for patients, showcasing his dedication to the pharmaceutical industry.

Collaborations

Angus Dalgleish collaborates closely with his colleague, Rachel Allen. Together, they work on various projects that leverage their expertise to develop innovative treatments and enhance patient care, demonstrating the power of teamwork in the often complex world of pharmaceuticals.

Conclusion

In summary, while Angus Dalgleish may not possess a portfolio of patents at this time, his contributions through LDN Pharma Limited and collaboration with peers like Rachel Allen reflect a commitment to innovation in the pharmaceutical landscape. The future could hold promising developments for him and the projects he undertakes.